UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia

Research recommendation(s) from an individual piece of guidance

Guidance:

UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia

Date issued:

04 May 2021

Research recommendations coming out of this guidance

• Further evidence to address uncertainties about the relative clinical and cost effectiveness of UroLift compared with Rezum, especially in the NHS, would be welcome. This should include:

  • exploring long-term clinical outcomes and reintervention rates after UroLift

  • assessing the suitability of UroLift for prostates larger than 80 ml and for those with an obstructive median lobe.